


**A FIRST-IN-CLASS  
DOUBLE INHIBITOR OF  
FLT3 AND PIM KINASES**

# MEN 1703

**MEN1703** is a first-in-class orally available double inhibitor of FLT3 and PIM kinases with a unique activity profile currently investigated for the treatment of Acute Myeloid Leukemia



PIM kinases have a role in cell survival and tumorigenesis and are upregulated in AML

FLT3-ITD: one of the most prevalent activating mutations (others are D835<sub>H/Y</sub> and N841)




PIM1 is upregulated by constitutively activated FLT3

PIM can phosphorylate FLT3

PIM expression is controlled by Janus kinases activation by cytokines or TKRs through STAT

# MEN 1703

AML is an aggressive and frequently lethal hematologic malignancy, with a median age of presentation beyond the sixth decade. The age-adjusted incidence rate of AML in the US has been described as 3.4 in 100,000 and in Europe its incidence has been observed at approximately 5-8 per 100,000. In the Western world, AML accounts for a quarter of all leukemias in adults, making it the most common form of leukemia in these areas.



MEN1703 showed an inhibition of the tumor burden growth in FLT3-ITD and FLT3 wt patient derived xenograft models.

Regardless specific prognostic factors, the overall 5-year survival for patients with AML is 25%, 40% for patients under age 60 years, and 10% for patients over age 60 years. Remission is achieved in the majority of patients, but relapse is common, particularly in older patients.



*"A Phase I/II Study of SEL24/MEN1703 in Patients With Acute Myeloid Leukemia"*  
NCT03008187

The purpose of the clinical trial is to identify the highest dose of **MEN1703** drug with acceptable safety profile to be used in patients with Acute Myeloid Leukemia.

The clinical trial encompasses two parts:

Part 1, ascending dose levels: the main purpose of this part of the clinical trial is to determine the highest dose of **MEN1703** considered to be well tolerated.

Part 2, expansion cohort: the main purpose of this part of the clinical trial is to assess the safety and anti-leukemia activity of **MEN1703** given at the highest tolerated dose in patient with Acute Myeloid Leukemia.